SCHEMBL24430048

SCHEMBL24430048

O=C(Nc1cccc2cccnc12)c1cc(F)c(O)c(F)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 6/20 0.67
▸ HDAC6 Q9UBN7 1/20 0.64
▸ MEN1 O00255 3/20 0.63
▸ KMT2A Q03164 3/20 0.63
▸ RAB9A P51151 3/20 0.63
▸ L3MBTL1 Q9Y468 2/20 0.63
▸ NPC1 O15118 2/20 0.63
▸ TDP1 Q9NUW8 1/20 0.62
▸ GAA P10253 1/20 0.62
▸ HTT P42858 1/20 0.62
▸ CASP3 P42574 1/20 0.62
▸ SENP8 Q96LD8 1/20 0.62
▸ SENP7 Q9BQF6 1/20 0.62
▸ SENP6 Q9GZR1 1/20 0.62
▸ HPGD P15428 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ MAPT P10636 3/20 0.58
▸ TP53 P04637 2/20 0.58
▸ LMNA P02545 1/20 0.58
▸ PKM P14618 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19422867 0.83 KDR (0.72) KDRHDAC6MEN1KMT2ARAB9A
SCHEMBL29911021 0.83 KDR (0.72) KDRHDAC6MEN1KMT2ARAB9A
SCHEMBL17552183 0.82 HDAC6 (0.77) KDRHDAC6MEN1KMT2ARAB9A
SCHEMBL29911198 0.82 HDAC6 (0.77) KDRHDAC6MEN1KMT2ARAB9A
SCHEMBL27782313 0.82 KDR (0.73) KDRHDAC6MEN1KMT2ARAB9A
SCHEMBL21356103 0.81 KDR (0.65) KDRHDAC6MEN1KMT2ARAB9A
SCHEMBL6260903 0.80 KDR (1.00) KDRHDAC6MEN1KMT2ARAB9A
SCHEMBL29434873 0.80 KDR (1.00) KDRHDAC6MEN1KMT2ARAB9A
SCHEMBL31565180 0.80 ALDH1A1 (0.64) KDRHDAC6MEN1KMT2ARAB9A
SCHEMBL27782316 0.80 MAPT (0.71) KDRHDAC6MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease SOUTHERN RES INST (US) 2023-10-26 — — US disclosed
WO-2022109067-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
US-20220153702-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease UAB RESEARCH FOUNDATION 2022-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153702-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, HMOX2, GLS KDR 2628/4885HDAC6 2005/4885MEN1 4651/4885
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, HMOX2, GLS KDR 2628/4885HDAC6 2005/4885MEN1 4651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback